Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.
about
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsThe role of ketamine in treatment-resistant depression: a systematic review.Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.Making assessment locally relevant: measuring functioning for maternal depression in Khayelitsha, Cape Town.Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.Development of the Global Disability Scale (Glo.Di.S): preliminary resultsMulti-modality: a new approach for the treatment of major depressive disorder.Patient-reported functioning in major depressive disorder.A review of antidepressant therapy in primary care: current practices and future directions.Study protocol: Hybrid Type I cost-effectiveness and implementation study of interpersonal psychotherapy (IPT) for men and women prisoners with major depressionSelf-stigma and quality of life in patients with depressive disorder: a cross-sectional study.Resilient Coping Moderates the Effect of Trauma Exposure on Depression.Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study.Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
P2860
Q33718213-A4AA4025-C1AB-481C-884E-7321D8CDECA5Q34449588-C599076A-7CAE-46B8-9603-6D8293E9103EQ34713784-241A99B3-EE3F-4583-BCD3-135472B266D1Q35707643-EECD414D-4546-4EB2-ACA7-243A213FDD7AQ36083249-9FE2726A-B756-4AB3-A903-5335E12E8D00Q36208461-4B77C046-276D-44E8-B845-03FC64589949Q36209425-CD5A3F53-15EA-4410-85B2-0F3F5D61E8F6Q36896252-E3488090-48CA-4B6F-90B6-DDF95A1F3398Q37002114-09B235A9-74D7-40C1-BED2-95D2416B2F95Q37070398-0AEAD00B-C333-4F86-A4DD-BE7747F93CE0Q37130486-1AAE8721-F233-48CF-A52F-FDE61202A5BCQ37361944-6F435DE3-FE82-45AB-8297-703EDC03439DQ39291019-8A1E842A-420F-49CA-AB2C-5E3C043FC175Q47640744-DFDD3267-F903-4C2B-9541-0904114BD8E0Q48069160-61BCF991-1BFB-4996-8E66-4FD66DA86B78Q55216925-4BB3B48D-6B13-4AE3-A9A4-F844B966555CQ57491808-B4E9A0C3-E7D6-483B-8D3F-C8B41ABED06D
P2860
Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Beyond symptomatic improvement ...... ith major depressive disorder.
@ast
Beyond symptomatic improvement ...... ith major depressive disorder.
@en
Beyond symptomatic improvement ...... ith major depressive disorder.
@nl
type
label
Beyond symptomatic improvement ...... ith major depressive disorder.
@ast
Beyond symptomatic improvement ...... ith major depressive disorder.
@en
Beyond symptomatic improvement ...... ith major depressive disorder.
@nl
prefLabel
Beyond symptomatic improvement ...... ith major depressive disorder.
@ast
Beyond symptomatic improvement ...... ith major depressive disorder.
@en
Beyond symptomatic improvement ...... ith major depressive disorder.
@nl
P2860
P356
P1476
Beyond symptomatic improvement ...... ith major depressive disorder.
@en
P2093
Alan M Langlieb
Christine J Guico-Pabia
P2860
P304
P356
10.4088/PCC.09R00826BLU
P577
2010-01-01T00:00:00Z